APA (7th ed.) Citation

V, N., J, S., S, A., Z, K., M, A., T, Y., . . . M, A. (2026). A novel hyperactive BCR: :ABL1 e6a3 variant confers resistance to combined asciminib plus ponatinib therapy. MedRxiv : the preprint server for health sciences. https://doi.org/10.64898/2026.04.14.26349982

Chicago Style (17th ed.) Citation

V, Nardi, et al. "A Novel Hyperactive BCR: :ABL1 E6a3 Variant Confers Resistance to Combined Asciminib Plus Ponatinib Therapy." MedRxiv : The Preprint Server for Health Sciences 2026. https://doi.org/10.64898/2026.04.14.26349982.

MLA (9th ed.) Citation

V, Nardi, et al. "A Novel Hyperactive BCR: :ABL1 E6a3 Variant Confers Resistance to Combined Asciminib Plus Ponatinib Therapy." MedRxiv : The Preprint Server for Health Sciences, 2026, https://doi.org/10.64898/2026.04.14.26349982.